-
1.
公开(公告)号:US20120196845A1
公开(公告)日:2012-08-02
申请号:US13499335
申请日:2010-10-01
IPC分类号: A61K31/4745 , A61K31/5377 , A61K31/496 , A61K31/506 , A61K31/519 , C07D519/00 , A61K31/498 , A61K31/52 , A61P25/28 , A61P25/18 , A61P29/00 , A61P25/00 , C07D471/04 , A61K31/501
CPC分类号: C07D405/04 , A61K31/535 , C07D401/14 , C07D405/14 , C07D409/14 , C07D417/14 , C07D471/04 , C07D473/00 , C07D487/02 , C07D491/056 , C07D495/04 , C07F7/0812
摘要: The present invention is directed to quinolinone-pyrazolone compounds of formula (I) which are M1 receptor positive allosteric modulators and that are useful in the treatment of diseases in which the M1 receptor is involved, such as Alzheimer's disease, schizophrenia, pain or sleep disorders. The invention is also directed to pharmaceutical compositions comprising the compounds, and to the use of the compounds and compositions in the treatment of diseases mediated by the M1 receptor.
摘要翻译: 本发明涉及式(I)的喹啉酮 - 吡唑啉酮化合物,其为M1受体阳性变构调节剂,可用于治疗涉及M1受体的疾病,例如阿尔茨海默氏病,精神分裂症,疼痛或睡眠障碍 。 本发明还涉及包含该化合物的药物组合物,以及该化合物和组合物在治疗由M1受体介导的疾病中的用途。